Download PDF
Hamostaseologie 1984; 04(04): 123-126
DOI: 10.1055/s-0038-1659935
Originaler Artikel
Schattauer GmbH

Hämostase beim hämolytisch-urämischen Syndrom

G. H. Neild
1   Renal Unit, Department of Medicine Guy’s Hospital, London, U. K.
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • Literatur

  • 1 Fong J.S.C, de Chadarevian J-R, Kaplan B.S. Haemolytic-uraemic syndrome: Current concepts and management. Paed. Clin. N. Amer. 29: 835-856 1982;
    PubMedGoogle Scholar
  • 2 Kaplan B.S, Drummond K.N. The haemolytic-uraemic syndrome is a syndrome. New Engl. J. Med. 298: 964-966 1978;
    CrossrefPubMedGoogle Scholar
  • 3 Robson J.S, Martin A.M, Ruckley V.A, MacDonald M.K. Irreversible postpartum renal failure. Quart. J. Med. 37: 423-435 1968;
    PubMedGoogle Scholar
  • 4 Brown C.B, Clarkson A.P, Robson J.S, Cameron J.S, Thomson D, Ogg C.S. Haemolytic-uraemic syndrome in women taking oral contraceptives. Lancet I: 1479-1481 1973;
    PubMedGoogle Scholar
  • 5 Kaplan B.S, Chesney R.W, Drummond K.N. Haemolytic-uraemic syndrome in families. New Engl. J. Med. 292: 1090-1093 1975;
    CrossrefPubMedGoogle Scholar
  • 6 Goldstein M.H, Churg J, Strauss L, Gribetz D. Haemolytic-uraemic syndrome. Nephron 23: 263-272 1979;
    CrossrefPubMedGoogle Scholar
  • 7 Koster F, Levin J, Walker L, Tung K.S.K, Gilman R.H. et al. Haemolyticuraemic syndrome after shigellosis. New Engl. J. Med. 298: 927-933 1978;
    CrossrefPubMedGoogle Scholar
  • 8 Bohle A, Helmchen U, Meyer D, Bock K.D, Brüning L, Edel H.H, Heimsoth V, Scheler F. Über die primäre und sekundäre maligne Nephrosklerose. Klin. Wschr. 51: 841-857 1973;
    CrossrefPubMedGoogle Scholar
  • 9 Riella M.C, George C.R.P, Hickman R.O, Striker G.E, Slichter S.J, Harker L, Quadracci L.J. Renal microangiopathy of the haemolytic uraemic syndrome in childhood. Nephron 17: 188-203 1976;
    CrossrefPubMedGoogle Scholar
  • 10 Hogewind B.L, Riviere G.B, van Es L.A, Veltkamp J.J. Familial occurrence of the haemolytic uraemic syndrome. Acta Med. Scand. 207: 73-77 1980;
    PubMedGoogle Scholar
  • 11 Remuzzi G, Marchesi D, Misiani R, Mecca G, de Gaetano G, Donati M.B. Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. Thromb. Res. 16: 517-525 1979;
    CrossrefPubMedGoogle Scholar
  • 12 Shulman H, Striker G, Deeg H.J, Kennedy M, Storb R, Thomas E.D. Nephrotoxicity of Cyclosporin A after allogeneic marrow transplantation: glomerular thrombosis and tubular injury. New Engl. J. Med. 305: 1392-1395 1981;
    CrossrefPubMedGoogle Scholar
  • 13 Jones B.G, Fielding J.W, Newman C.E, Howell A, Brookes V.S. Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C. Lancet I: 1275-1277 1980;
    PubMedGoogle Scholar
  • 14 Whitington P.F, Friedman A.L, Chesney R.W. Gastrointestinal disease in the haemolytic-uraemic syndrome. Gastroenterology 76: 728-733 1979;
    PubMedGoogle Scholar
  • 15 Ridolfi R.L, Bell W.R. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) 60: 413-428 1981;
    CrossrefPubMedGoogle Scholar
  • 16 Atkinson K, Biggs J.C, Hayes J, Ralston M, Dodds A.J. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Brit. J. Haematol. 54: 59-67 1983;
    CrossrefPubMedGoogle Scholar
  • 17 Hellman R.M, Jackson D.V, Buss D.H. Thrombotic thrombocytopenic purpura and haemolytic syndrome in HLA-identical siblings. Ann. Intern. Med. 93: 287-7 1980;
    PubMedGoogle Scholar
  • 18 Dormandy T.L. Free-radical oxidation and anti-oxidants. Lancet I: 647-650 1978;
    PubMedGoogle Scholar
  • 19 Fantone J.C, Ward P.A. Role of oxygen-derived free radicals and metabolites in leucocyte-dependent inflammatory reactions: review article. Amer. J. Pathol. 107: 397-418 1982;
    PubMedGoogle Scholar
  • 20 Nafstad I. Endothelial damage and platelet thrombosis associated with PUFA-rich, vitamin E deficient diet fed to pig. Thromb. Res. 5: 251-255 1974;
    CrossrefPubMedGoogle Scholar
  • 21 Teige J, Nordstoga K, Fjolstad M, Nafstad I. The generalised Shwartzman reaction in pigs induced by diet and single injection of endotoxin from Escherichia coli. Acta Vet. Scand. 14: 92-106 1973;
    PubMedGoogle Scholar
  • 22 Stuart M.J. Deficiency of plasma PGI2-like regenerating activity in neonatal plasma. Reversal by vitamin E in vitro. Pediatr. Res. 15: 971-973 1981;
    CrossrefPubMedGoogle Scholar
  • 23 Brain M.C, Dacie J.V, Hourihane DO-B. Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis. Brit. J. Haematol. 8: 358-371 1962;
    CrossrefPubMedGoogle Scholar
  • 24 Stocks J, Offerman E.L, Modell C.B, Dormandy T.L. The susceptibility to auto-oxidation of human red-cell lipids in health and disease. Br. J. Haematol. 23: 713-724 1972;
    CrossrefPubMedGoogle Scholar
  • 25 O’Regan S, Chesney R.W, Kaplan B.S, Drummond K.N. Red cell membrane phospholipid abnormalities in the haemolytic uraemic syndrome. Clin. Nephrol. 5: 14-17 1980;
    PubMedGoogle Scholar
  • 26 Remuzzi G, Misiani R, Marchesi D, Livio M, Mecca G. et al. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?. Lancet II: 871-872 1978;
    PubMedGoogle Scholar
  • 27 Chen Y-C, McLeod B, Hall E.R, Wu K.K. Accelerated prostacyclin degradation in thrombotic thrombocytopenic purpura. Lancet II: 267-269 1981;
    PubMedGoogle Scholar
  • 28 Carreras L.O, Defreyn G, Machin S.J, Vermylen J, Deman R, Spitz B, van Assche A. Arterial thrombosis, intrauterine death and »lupus« anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet I: 244-246 1981;
    PubMedGoogle Scholar
  • 29 Zoja C, Arnout J, Deckmyn H, Vermylen J. Partial purification and characterization of the prostacyclin stimulating plasma factor (PSPF). Thromb. Haemostas. 50:Abstr. 0751 1983
    PubMedGoogle Scholar
  • 30 Lian EC.-Y, Harkness D.R, Byrnes J.J, Wallach H, Nunez R. Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura and its inhibition by normal plasma. Blood 53: 333-338 1979;
    PubMedGoogle Scholar
  • 31 Görög P, Schraufstätter I, Born G.V.R. Effect of removing sialic acids from endothelium on the adherence of circulating platelets in arteries in vivo. Proc. R. Soc. Lond. B214: 471-480 1982;
    CrossrefPubMedGoogle Scholar
  • 32 Metz J. Observations on the mechanism of the haematological changes in the haemolytic uraemic syndrome of infancy. Brit. J. Haematol. 23 (suppl.) 53-59 1972;
    CrossrefPubMedGoogle Scholar
  • 33 Burns E.R, Zucker-Franklin D. Pathological effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured endothelial cells. Blood 60: 1030-1037 1982;
    PubMedGoogle Scholar
  • 34 Bergstein J.M, Michael A.F. Renal cortical fibrinolytic activity in the rabbit following one or two doses of endotoxin. Thromb. Diath. Haemorrh. 29: 27-32 1973;
    PubMedGoogle Scholar
  • 35 Bergstein J.M, Kuederli V, Bang N.U. Plasma inhibitor of glomerular fibrinolysis in the haemolytic-uraemic syndrome. Amer. J. Med. 73: 322-327 1982;
    CrossrefPubMedGoogle Scholar
  • 36 Katz J, Krawitz S, Sacks P.V, Levin S.E, Thomson P, Levin J, Metz J. Platelet, erythrocyte and fibrinogen kinetics in the haemolytic uraemic syndrome of infancy. J. Paediatr. 83: 739-748 1973;
    CrossrefPubMedGoogle Scholar
  • 37 Fong J.S.C, Kaplan B.S. Impairment of platelet aggregation in haemolytic uraemic syndrome: evidence for platelet »exhaus-tion«. Blood 60: 564-570 1982;
    PubMedGoogle Scholar
  • 38 Pared F.I, Capitanio A, Mannucci L, Ponticelli C, Mannucci P.M. Acquired dysfunction due to the circulation of »exhaus-ted« platelets. Amer. J. Med. 69: 235-240 1980;
    CrossrefPubMedGoogle Scholar
  • 39 Kamitsuji H, Kusumoto K, Taira K, Iida Y, Nakajima M, Fukui H. Localization of intrarenal cross-linked fibrin in children with various renal diseases. Nephron 35: 94-99 1983;
    CrossrefPubMedGoogle Scholar
  • 40 Brandt P, Jespersen J, Gregersen G. Post-partum haemolytic-uraemic syndrome treated with antithrombin III. Nephron 27: 15-18 1981;
    CrossrefPubMedGoogle Scholar
  • 41 Monnens L, de Jong M, van Oostrom C, van Munster P. Antithrombin III levels in children with the epidemic form of haemolytic-uraemic syndrome. Nephron 32: 261-262 1982;
    CrossrefPubMedGoogle Scholar
  • 42 Misiani R, Appiani A.C, Edefonti A, Gotti E, Bettinelli A, Giani M, Rossi E, Remuzzi G, Mecca G. Haemolytic-uraemic syndrome: therapeutic effect of plasma infusion. Brit. Med. J. 285: 1304-1306 1982;
    CrossrefPubMedGoogle Scholar
  • 43 Brown R.A. Failure of fibronectin as an opsonin in the host defence system: a case of competitive self-inhibition?. Lancet II: 1058-1060 1983;
    PubMedGoogle Scholar
  • 44 Defreyn G, Proesmans W, Machin S.J, Lemmens F, Vermylen J. Abnormal prostacyclin metabolism in the haemolytic uraemic syndrome: equivocal effect of prostacyclin infusions. Clin. Nephrol. 18: 43-49 1982;
    PubMedGoogle Scholar
  • 45 Seid J.M, Jones P.B.B, Russell R.G.G. The presence in normal plasma, serum and platelets of factors that stimulate the production of prostacyclin by cultured endothelial cells. Clin. Sci. 64: 387-394 1983;
    CrossrefPubMedGoogle Scholar
  • 46 Saba H.O, Saba S.R, Blackburn C.A, Hartmann R.C, Mason R.G. Heparin neutralisation of prostacyclin: effects upon platelets. Science 205: 499-501 1979;
    CrossrefPubMedGoogle Scholar
  • 47 Salzman E.W, Rosenberg R.D, Smith M.H, Lindon J.N, Favreau L. Effect of heparin and heparin fraction on platelet aggregation. J. Clin. Invest. 65: 64-73 1980;
    CrossrefPubMedGoogle Scholar
  • 48 Trompeter R.S, Schwartz R, Chantier C, Dillon M.J, Haycock G.B, Kay R, Barrati T.M. Haemolytic-uraemic syndrome: an analysis of prognostic features. Arch. Dis. Childh. 58: 101-105 1983;
    CrossrefPubMedGoogle Scholar